BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q2 EPS of ($0.66), $0.30 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $54.02 million versus the consensus estimate of $29.12 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.